摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4aS)-trans-decahydroquinoline | 22160-37-8

中文名称
——
中文别名
——
英文名称
(4aS)-trans-decahydroquinoline
英文别名
(4aS)-trans-Decahydrochinolin;trans-(+)-decahydro-quinoline;trans-Decahydrochinolin;trans-Dekahydrochinolin;(4aR,8aS)-decahydroquinoline;(4aS,8aR)-1,2,3,4,4a,5,6,7,8,8a-decahydroquinoline
(4a<i>S</i>)-<i>trans</i>-decahydroquinoline化学式
CAS
22160-37-8
化学式
C9H17N
mdl
——
分子量
139.241
InChiKey
POTIYWUALSJREP-DTWKUNHWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    12
  • 氢给体数:
    1
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    (4aS)-trans-decahydroquinoline 在 sodium tetrahydroborate 、 碘苯二乙酸 作用下, 以 2,2,2-三氟乙醇 为溶剂, 反应 19.0h, 生成 1-azabicyclo[5.3.0]decane
    参考文献:
    名称:
    NH哌啶环收缩为吡咯烷的氧化重排方法
    摘要:
    我们开发了一种利用 PhI(OAc)2 氧化重排来收缩 N-H 哌啶环的方法。该反应形成亚胺离子中间体,该中间体被亲核试剂(例如NaBH4、H2O)有效捕获,产生相应的吡咯烷衍生物。此外,我们提出了一种由实验和密度泛函理论计算支持的离子机制。
    DOI:
    10.1002/adsc.202400484
  • 作为产物:
    描述:
    alkaline earth salt of/the/ methylsulfuric acid 在 <(1R)-(endo,anti)>-(+)-3-bromocamphor-8-sulfonic acid 作用下, 生成 (4aS)-trans-decahydroquinoline
    参考文献:
    名称:
    Veneziani, Atti della Accademia Nazionale dei Lincei, Classe di Scienze Fisiche, Matematiche e Naturali, Rendiconti, 1913, vol. <5> 22 II, p. 155
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • A General Protocol for the Broad-Spectrum Cross-Coupling of Nonactivated Sterically Hindered 1° and 2° Amines
    作者:Abir Khadra、Stanislas Mayer、David Mitchell、Michael J. Rodriguez、Michael G. Organ
    DOI:10.1021/acs.organomet.7b00490
    日期:2017.9.25
    While notable advances have been reported for the metal-catalyzed cross-coupling of bulky amines, to date no set of reported conditions has proven general for both hindered and unactivated primary and secondary amines. Examples that are reported with Pd catalysts invariably involve aggressive alkoxide bases in order to provide the necessary “push” required to couple these challenging substrates. Consequently
    尽管已经报道了大体积胺的金属催化的交叉偶联的显着进展,但是迄今为止,对于受阻和未活化的伯胺和仲胺,没有任何报道的条件被证明是普遍的。Pd催化剂报道的例子总是涉及侵蚀性醇盐碱,以提供偶联这些具有挑战性的底物所需的必要“推动”。因此,在涉及此类底物的公开报告中几乎没有(如果有的话)对碱敏感的官能团(例如,酯,酮,氰基)被包括在内。本文中我们公开了Pd-PEPPSI-IPent Cl 3-氯吡啶的用途 在一个单一方案中使用温和但可溶的碱式丁基化羟基甲苯钠(NaBHT)制成的预催化剂,该方案可以偶联各种受阻和未活化的伯胺和仲胺,从而以高收率生产官能化产物。
  • CORROSION INHIBITION
    申请人:SCHLUMBERGER TECHNOLOGY CORPORATION
    公开号:US20180312980A1
    公开(公告)日:2018-11-01
    A corrosion inhibiting compound with a general structure A-B or A-X-B for inhibition of corrosion of steel in acidic solution. A comprises a heterocyclic ring system having a plurality of cyclic Carbon atoms and at least one cyclic Nitrogen atom, wherein the at least one cyclic Nitrogen atom is neutral under neutral conditions and protonatable under acidic conditions. B comprises at least two unsaturated Carbon atoms. B may comprise a ring system or a polymerisable group.
    一种具有一般结构A-B或A-X-B的防腐蚀化合物,用于抑制钢材在酸性溶液中的腐蚀。A包括具有多个环状碳原子和至少一个环状氮原子的杂环系统,其中至少一个环状氮原子在中性条件下是中性的,在酸性条件下可以质子化。B包括至少两个不饱和碳原子。B可以包括一个环系统或一个可聚合基团。
  • Regulating the growth of plants and controlling weeds with
    申请人:Ciba-Geigy Corporation
    公开号:US03941579A1
    公开(公告)日:1976-03-02
    Substituted azabicycloalkanes of the formula I ##EQU1## wherein R represents an alkyl radical which contains 2 or 3 carbon atoms and is substituted by chlorine or a straight-chain or branched alkenyl radical containing 3 or 4 carbon atoms, R.sub.1 and R.sub.2 represent hydrogen or the one represents methyl and the other represents hydrogen, and n is the number 1 or 2, may be used for influencing the growth of plants, preferably for combating weeds in rice-cultures.
    式I的替代的偶氮杂环烷,其中R代表含有2或3个碳原子并被氯或直链或支链烯基基团取代的烷基基团,该烯基基团含有3或4个碳原子,R1和R2代表氢或其中一个代表甲基,另一个代表氢,n是数字1或2,可以用于影响植物的生长,优选用于在稻田中作为除草剂。
  • Ophthalmic Compositions for Treating Ocular Hypertension
    申请人:Doherty James B.
    公开号:US20090062280A1
    公开(公告)日:2009-03-05
    This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
    本发明涉及在治疗青光眼和其他导致患者眼内压升高的疾病中使用强效钾通道阻滞剂或其配方。本发明还涉及使用这些化合物在哺乳动物,特别是人类的眼中提供神经保护作用。
  • Thiazoles as inhibitors of 11B-hydroxysteroid dehydrogenase
    申请人:Gillespie Paul
    公开号:US20070167622A1
    公开(公告)日:2007-07-19
    Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.
    本文提供了公式(I)的化合物及其药用可接受盐,其中取代基如规范中所述。这些化合物及其含有的药物组合物,可用于治疗疾病,例如II型糖尿病和代谢综合征。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
mass
查看更多图谱数据,请前往“摩熵化学”平台
ir
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

锯齿石松宁 箭毒蛙毒素 C 坎库碘铵 十氢喹啉 十氢-2-甲基喹啉 八氢对苯二酚-4(1H)-酮 八氢喹啉-2(1H)-酮 八氢-2,6-喹啉二酮 [(4aS,4bR,6aS,8S,10aS,10bS,12aS)-10a,12a-二甲基-1,2,3,4,4a,4b,5,6,6a,7,8,9,10,10b,11,12-十六氢萘并[6,5-f]喹啉-8-基]2-[4-[二(2-氯乙基)氨基]苯基]乙酸酯 [(4aS,4bR,6aS,8S,10aS,10bS,12aS)-1,10a,12a-三甲基-2-氧代-3,4,4a,4b,5,6,6a,7,8,9,10,10b,11,12-十四氢萘并[6,5-f]喹啉-8-基]2-[4-[二(2-氯乙基)氨基]苯基]乙酸酯 8H-13,3,6a-乙基亚基-7,10-亚甲基噁庚并[3,4-i]-1-苯并吖辛因-8-酮,1-乙基十四氢-12a-羟基-6-甲氧基-3-甲基-,(3R,6S,6aS,7R,7aS,10S,12aS,13S,13aR,15R)-(9CI) 8-羟基-十氢喹啉 4-乙炔基-2-甲基十氢喹啉-4-醇 3-羟基-13,17-开环-5-雄甾烯-17-酸-13,17-内酰胺(4-(二(2-氯乙基)氨基)苯基)丁酸酯 2,5-二丙基十氢喹啉 1-(3-氯-丙基)-十氢-喹啉 1,2,2-三甲基-八氢-喹啉-4-酮 (4aS,4bR,8S,10aR,10bS,12aS)-10a,12a-二甲基-2-羰基-1,2,3,4,4a,4b,5,7,8,9,10,10a,10b,11,12,12a-十六氢萘并[2,1-f]喹啉-8-基{4-[二(2-氯乙基)氨基]苯基}乙酸酯 (4aS,4bR,6aS,8S,10aS,10bS,12aS)-8-羟基-10a,12a-二甲基-3,4,4a,4b,5,6,6a,7,8,9,10,10b,11,12-十四氢-1H-萘并[2,1-f]喹啉-2-酮 (3S,13R)-1,2,3,4,4aalpha,5,11,11aalpha-八氢-2,2,5-三甲基-3beta,5beta-乙桥-10bH-吡啶并[3,2-b]咔唑-10bbeta,13-二醇 (3R,6S,6aS,7R,7aS,10S,12aS,13R,13aR,14S,15R)-1-乙基十四氢-12a,14-二羟基-6-甲氧基-3-甲基-8H-13,3,6a-亚乙基-7,10-甲桥氧杂卓并[3,4-i]-1-苯并氮杂环辛四烯-8-酮 (2S,4aR,8aR)-2-甲基八氢-4(1H)-喹啉酮 (2R,4R,4As,8As)-rel-4-乙炔基十氢-1,2-二甲基-4-喹啉醇 (4aS,5R,8aR)-1-(tert-butoxy)carbonyl-2-oxo-5-(triisopropylsilyloxymethyl)decahydroquinoline trans-(+/-)-1-n-propyl-7-oxodecahydroquinoline 3,4,5,6,6a,7,8,9,10,10a-decahydro-(4aβH)-benzo[c]quinolizin-3-one 3,4,5,6,6a,7,8,9,10,10a-decahydro-(4aαH)-benzo[c]quinolizin-3-one 3,4,4a,5,6,7,8-heptahydro-8a-hydrodioxy-2(1H)-quinolinone [2-(2,3-dichloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone (octahydro-quinolin-1-yl)-(2-pyridin-3-yl-thiazol-4-yl)-methanone 2-methylperhydrothiazolo<2,3-j>quinoline 2,4-dichloro-N-[5-((4aRS,8aSR)-octahydroquinoline-1-carbonyl)pyridin-2-yl]benzamide (4aR*,5S*,8aR*)-1,2,3,4,4a,5,6,7,8,8a-Decahydro-5-<(dimethylphenylsilyl)methyl>-1-methylquinoline (4aS*,5S*,8aR*)-1,2,3,4,4a,5,6,7,8,8a-Decahydro-5-<(dimethylphenylsilyl)methyl>-1-(methoxycarbonyl)quinoline (2S,3R,4aS,5R,8aR)-1-(tert-butoxy)carbonyl-3-hydroxy-2-methyl-5-(triisopropylsilyloxymethyl)decahydroquinoline (+/-)-(2SR,4aRS,8aRS)-1-tert-butyloxycarbonyl-5-methylene-2-propyldecahydroquinoline (+/-)-(2SR,4aRS,8aRS)-1-tert-butyloxycarbonyl-2-propyldecahydroquinolin-5-one cis-4-[4-(octahydro-quinoline-1(2H)-ylcarbonyl)-thiophen-2-yl]-piperidine-1-carboxylic acid amide lepadin E (+)-lepadin D cis-(octahydro-quinolin-1(2H)-yl)-(5-piperidin-4-yl-thiophen-3-yl)-methanone 4-methyl-6-(3-methyl-2-thienyl)-4,5,6,7-tetrahydroquinolin-5-one 2,2,4,8-tetramethyldecahydroquinoline 10-oxo-2,5;5,9-diseco-A-dinor-strychnidine-2,5-dioic acid strychnidine-2,3,10-trione 3-tetrazolo-17a-aza-D-homo-3,5-androstadien-17-one 17a-methyl-3-tetrazolo-17a-aza-D-homo-3,5-androstadien-17-one methyl 4-oxooctahydroquinoline-1(2H)-carboxylate decahydro-2-oxo-8-quinolinepropanoic acid ethyl ester 1-octahydro[1]quinolyl-propan-2-ol